Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Developing a simplified ex vivo culturing protocol for personalized myeloma treatment in rural areas

Zhi Wen, Adam Bissonnette, Luke Moat et al. Nov 03, 2025 pp. 4332-4332 10.1182/blood-2025-4332

Abstract Background: Multiple myeloma (MM) is the second most common hematologic malignancy in the United States, with over 30,000 new cases...

Real-world outcomes of standard and modified daratumumab-based therapy in AL amyloidosis: A cohort study from a multidisciplinary program in south India

Neeraj Sidharthan, Vivek Ananda Chood O M, Anandakrishnan Nandakumar et al. Nov 03, 2025 pp. 2820-2820 10.1182/blood-2025-2820

Abstract Background: Systemic light chain (AL) Amyloidosis is a rare plasma cell dyscrasia with an estimated global incidence of 10–15 cases...

Real world epidemiological trends in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), England 2014-2021: Preliminary data from the uncover Study group

Indrani Karpha, Nurunnahar Akter, Temitope Erinfolami et al. Nov 03, 2025 pp. 6298-6298 10.1182/blood-2025-6298

Abstract Introduction NLPHL is a rare, indolent lymphoma, traditionally considered a subtype of Hodgkin lymphoma (HL), with an excellent pro...

Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a phase 2 trial

Andrew Lane, Marlise Luskin, Julia Keating et al. Nov 03, 2025 pp. 653-653 10.1182/blood-2025-653

Abstract Background: BPDCN is an aggressive, orphan hematologic malignancy characterized by multi-organ involvement including skin, blood, b...

Venetoclax plus obinutuzumab improves quality of life in treatment-naive CLL: Prospective real-world insights from the verve study

Ingo Schwaner, Holger Hebart, Thomas Wolff et al. Nov 03, 2025 pp. 2117-2117 10.1182/blood-2025-2117

Abstract Introduction: Fixed-Duration venetoclax plus obinutuzumab (VenO) has shown efficacy and safety in patients with 1L CLL, establishin...

PRKRA associated with NF-κB activation in pulmonary involvement of idiopathic multicentric castleman disease

Yu-han Gao, Cong-Wei Jia, Zhi-Yuan Li et al. Nov 03, 2025 pp. 4784-4784 10.1182/blood-2025-4784

Abstract Idiopathic multicentric Castleman disease (iMCD) is a heterogeneous group of HIV- and HHV-8-negative lymphoproliferative disorders...

Real-world comparative effects of curative and disease-modifying therapies on ineffective erythropoiesis in beta-thalassemia

Carlo Castruccio Castracani, Madison Bright, Jaladhikumar Patel et al. Nov 03, 2025 pp. 176-176 10.1182/blood-2025-176

Abstract Introduction In beta-thalassemia (BT), reduced or absent production of beta globin leads to the accumulation of excess alpha globin...

Prognostic factors for newly diagnosed Acute Myeloid Leukemia with FLT3-TKD - a multicenter retrospective study

Jiaying Lian, Yu Zhu, Zhiling Yan et al. Nov 03, 2025 pp. 5182-5182 10.1182/blood-2025-5182

Abstract Background: Acute myeloid leukemia (AML) is characterized by significant heterogeneity, with cytogenetic and molecular genetic feat...

Machine learning-based classification of chronic lymphocytic leukemia signalotypes to allows biological and clinical insights into novel CLL subgroups

Daniela Asslaber, Jennifer Forster, Tina Hofer et al. Nov 03, 2025 pp. 3877-3877 10.1182/blood-2025-3877

Abstract Introduction: The mutational landscape of chronic lymphocytic leukemia (CLL) is characterized by a broad spectr...

The role of sole loss of chromosome y in myeloid neoplasms

Sandra Huber, Stephan Hutter, Manja Meggendorfer et al. Nov 03, 2025 pp. 1390-1390 10.1182/blood-2025-1390

Abstract Background: Loss of chromosome Y (LOY) is one of the most common acquired age-related somatic genomic alteratio...

A Phase 1 study evaluating NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel (tisa-cel), post-axicabtagene ciloleucel (axi-cel), or post-lisocabtagene maraleucel (liso-cel) in Relapsed/Refractory large B-cell lymphoma

Zachary Crees, Armin Ghobadi, Elizabeth Budde et al. Nov 03, 2025 pp. 926-926 10.1182/blood-2025-926

Abstract Autologous CD19 CAR T-cell therapy (CART19) for relapsed/refractory large B-cell lymphoma (r/r LBCL) enables high objective respons...

Structure-guided discovery of potent acly inhibitors with therapeutic potential in ALK+ anaplastic large cell lymphoma and other hematologic malignancies

Nagarajan Pattabiraman, Cosimo Lobello, David Rushmore et al. Nov 03, 2025 pp. 6815-6815 10.1182/blood-2025-6815

Abstract Background: ATP-citrate lyase (ACLY) is a central metabolic enzyme that produces cytosolic acetyl-CoA, a key metabolite linking cel...

Phase II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML

Wei-Ying Jen, Courtney DiNardo, Nicholas Short et al. Nov 03, 2025 pp. 47-47 10.1182/blood-2025-47

Abstract Background The menin–KMT2A interaction is a dependency in acute leukemia caused by NPM1 mutations (NPM1m) or rearrangements of KMT2...

Identification of the MIF-CD74/CD44 signaling axis as a therapeutic target in pediatric Acute Myeloid Leukemia

Morgan Anderson-Crannage, Meijuan Tian, Mishel Ramirez et al. Nov 03, 2025 pp. 6786-6786 10.1182/blood-2025-6786

Abstract Introduction: Acute myeloid leukemia (AML) accounts for ~25% of pediatric leukemia cases and is associated with poor prognosis and...

Connecting pharmacokinetic exposure to immune reconstitution: A pilot study in HLA-haploidentical hematopoietic cell transplant recipients

Guofang Shen, Tim Synold, Shanzay Khan et al. Nov 03, 2025 pp. 7768-7768 10.1182/blood-2025-7768

Abstract Post-transplant cyclophosphamide (PTCy) and mycophenolate mofetil (MMF) are commonly used in combination with tacrolimus or sirolim...

Immune subset clonality profiling in aplastic anemia: A highly sensitive flow cytometry approach to differentiate acquired and inherited syndromes.

Sudhanshi Raina, Sreejesh Sreedharanunni, Man Updesh Singh Sachdeva et al. Nov 03, 2025 pp. 4972-4972 10.1182/blood-2025-4972

Abstract Background: Inherited bone marrow failure syndromes (IBMFS), such as Fanconi anemia, and acquired aplastic anem...

Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Susan Bal, Luciano Costa, Nizar Bahlis et al. Nov 03, 2025 pp. 5807-5807 10.1182/blood-2025-5807

Abstract Background and Significance: MM is a highly heterogenous disease and novel therapies are required to better address pt needs and im...

Phase 1/2, multi-center, open-label clinical study to evaluate the safety, pharmacokinetics, and efficacy of Zefamenib combined with chemotherapy or targeted Agents in patients with Acute Myeloid Leukemia

Haiping Dai, Depei Wu, Suning Chen et al. Nov 03, 2025 pp. 8257-8257 10.1182/blood-2025-8257

Abstract Background: Acute myeloid leukemia (AML) accounts for approximately 70-75% of all adult patients diagnosed with acute leukemia. Nuc...

FAM46C/Tent5c inactivation accelerates multiple myeloma progression from early stages and remodels the bone marrow immune microenvironment in preclinical models

Carmen Vicente, Marta Larrayoz, Bachisio Ziccheddu et al. Nov 03, 2025 pp. 1027-1027 10.1182/blood-2025-1027

Abstract FAM46C/Tent5c, a non-canonical polyA-polymerase expressed by plasma cells, is recurrently mutated, or genetically deleted, in 20% o...

Single-cell dissection of pathogenic T-cell response to tacrolimus in immune thrombocytopenia

Li-Ping Yang, Peng Zhao, Qiu-Sha Huang et al. Nov 03, 2025 pp. 3024-3024 10.1182/blood-2025-3024

Abstract IntroductionPrimary immune thrombocytopenia (ITP) is an autoimmune disease characterized by excessive platelet destruction and decr...

Evolving catastrophic antiphospholipid syndrome with intracerebral hemorrhage: Treatment with plasma exchange and rituximab

Paul Wurtz, David Pratico, Devin Moore et al. Nov 03, 2025 pp. 6650-6650 10.1182/blood-2025-6650

Abstract Title When Anticoagulation Falls Short: Immunomodulation in Severe Antiphospholipid Syndrome...

Preliminary safety and efficacy of boven (Zanubrutinib, Obinutuzumab, and Venetoclax) as frontline therapy for older patients with Mantle Cell Lymphoma

Anita Kumar, Jacob Soumerai, Reem Karmali et al. Nov 03, 2025 pp. 888-888 10.1182/blood-2025-888

Abstract Background: Frontline mantle cell lymphoma (MCL) treatments are rapidly evolving with incorporation of targeted therapies. We previ...

The Impact of the number of cytogenetic abnormalities on clinical outcomes in Acute Myeloid Leukemia with complex karyotype

Moath Albliwi, Emily Zabor, John Hanna et al. Nov 03, 2025 pp. 1628-1628 10.1182/blood-2025-1628

Abstract Background Acute myeloid leukemia (AML) is a biologically heterogeneous malignancy and is usually associated with poor prognosis. C...

Adverse financial events and delayed treatment initiation among patients with hematologic malignancies

Christopher Su, Li Li, Catherine Fedorenko et al. Nov 03, 2025 pp. 286-286 10.1182/blood-2025-286

Abstract Background For patients with hematologic malignancies (diffuse large B-cell lymphoma [DLBCL], multiple myeloma [MM], and chronic my...

Chidamide with the methotrexate, ifosfamide, etoposide, doxorubicin liposomes, and dexamethasone (MIEDD) regimen improves efficacy and safety in newly diagnosed primary CNS T-cell lymphoma

Jing Liu, Xuefei Sun, Qu Cui et al. Nov 03, 2025 pp. 5418-5418 10.1182/blood-2025-5418

Abstract BackgroundDiffuse large B-cell lymphoma, a common subtype of primary central nervous system (CNS) lymphoma, has been increasingly s...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page